Ketamine can be safe for depression when administered in a controlled medical setting, but it carries real risks that vary depending on the dose, how it’s given, and your medical history. The FDA-approved nasal spray form (esketamine) requires a two-hour monitored observation period after every single dose, which tells you something about how seriously regulators take its side effect profile. For the right patient, the benefits can outweigh those risks. For others, ketamine may be genuinely dangerous.
How Ketamine Works Differently Than Other Antidepressants
Traditional antidepressants take weeks to build up in your system. Ketamine works within hours, and it does so through a completely different mechanism. Rather than targeting serotonin or norepinephrine, ketamine blocks a specific type of receptor in the brain involved in glutamate signaling, the brain’s primary excitatory chemical messenger. This triggers a cascade: glutamate levels temporarily surge, which strengthens connections between neurons and essentially helps the brain rewire weakened circuits.
Think of it as a reset. Depression shrinks the connections between nerve cells over time, particularly in areas responsible for mood and motivation. Ketamine promotes rapid growth of new synaptic connections, a process called synaptogenesis. This is why people with severe, treatment-resistant depression can sometimes feel markedly better within a day of their first dose, something no conventional antidepressant can do.
What Side Effects to Expect
The most common acute side effects are dissociation (a floating, detached-from-reality feeling), dizziness, nausea, sedation, and temporary increases in blood pressure. Dissociation is not a rare occurrence. It’s expected and is one of the main reasons you’re monitored after each dose. For most people it resolves within two hours, but it can be unsettling, especially the first time.
More serious acute reactions include hallucinations, agitation, abnormal muscle movements, and in rare cases, respiratory depression where breathing slows significantly. Blood pressure spikes are common enough that clinicians are required to check your blood pressure before dosing and again about 40 minutes afterward. If you have uncontrolled high blood pressure or other cardiovascular problems, ketamine poses a real danger.
You’ll be told to avoid food for at least two hours before treatment and liquids for 30 minutes before, since nausea and vomiting are common. You also cannot drive for the rest of the day and need to arrange a ride home.
Cognitive Effects During Treatment
One of the biggest concerns people have is whether ketamine will affect their thinking or memory. The evidence so far is reassuring for medically supervised, low-dose treatment. A systematic review and meta-analysis across multiple trials found that therapeutic ketamine doses had no significant overall effect on cognition. Attention, processing speed, and most memory measures stayed stable.
There was one exception: a small but measurable dip in verbal learning performance showed up across three studies, suggesting some people may have slightly more difficulty retaining new verbal information during a treatment course. However, some studies found the opposite pattern. Patients who responded well to ketamine actually showed improvements in sustained attention and impulse control, likely because lifting severe depression itself improves cognitive function. The picture is nuanced, and the cognitive effects of untreated severe depression are themselves substantial.
The Addiction Question
Ketamine is a Schedule III controlled substance, and yes, it can be addictive. This is not a theoretical concern. Ketamine acts quickly and produces strong effects, two characteristics that make any drug more prone to misuse. The risk is highest for people with a history of substance use disorder, whether with alcohol, opioids, or other drugs.
In a supervised clinical setting where doses are controlled and the drug is never sent home with patients, the addiction risk is significantly lower than with recreational use. But it’s not zero. Clinicians should screen carefully for substance use history before starting treatment, and patients who notice themselves craving treatments or seeking ketamine outside the clinical setting should flag that immediately.
Bladder and Urinary Tract Damage
This is the long-term risk that gets the least attention but may be the most concerning for people on extended treatment. Roughly 3 in 10 regular ketamine users develop what’s called ketamine bladder, a condition where the drug damages the bladder lining, making it stiff and shrunken. Symptoms include frequent urination (including at night), urgency, pelvic pain, blood in urine, and pain while urinating. In severe cases, ketamine can block the tubes connecting the kidneys to the bladder, potentially leading to kidney failure.
Most of the data on bladder damage comes from recreational users taking much higher and more frequent doses than what’s used in depression treatment. But the risk isn’t absent at therapeutic doses, particularly for patients receiving repeated infusions over months or years. This is an area where the long-term safety data for depression treatment is still limited, and it’s worth discussing with your provider if you’re considering ongoing ketamine therapy.
Who Should Not Use Ketamine
The FDA has flagged several conditions that make ketamine unsafe or require extreme caution. Uncontrolled high blood pressure is a primary concern because ketamine reliably raises blood pressure. People with a history of psychosis or active psychotic symptoms face the risk of psychiatric worsening. Those with aneurysmal vascular disease or other conditions where a blood pressure spike could be catastrophic should avoid it entirely.
A history of addiction is not an absolute barrier, but it demands careful risk assessment. The FDA has also warned specifically about compounded ketamine products sold through telemedicine platforms and online pharmacies, noting safety concerns around abuse, psychiatric events, blood pressure changes, and respiratory depression when ketamine is used outside supervised settings.
FDA-Approved vs. Off-Label Ketamine
There are two distinct worlds of ketamine for depression. The FDA-approved version is esketamine (brand name Spravato), a nasal spray approved for treatment-resistant depression in adults and for adults with major depression who have acute suicidal thoughts or behavior. It must be taken alongside an oral antidepressant and can only be administered in a certified healthcare setting. It is never dispensed for home use. A prescriber must be onsite during administration, and a healthcare provider monitors you for at least two hours afterward, including pulse oximetry to track your breathing.
The other world is off-label IV ketamine, offered at private clinics across the country. These infusions use racemic ketamine, the original form of the drug, which is not FDA-approved for depression but is legally prescribed off-label. A meta-analysis published in The Lancet found that racemic ketamine at higher doses produced larger improvements in depression severity, response rates, and remission rates compared to esketamine. The antidepressant effects of racemic ketamine also persisted longer after the final dose. However, off-label clinics operate with less regulatory oversight than the Spravato REMS program, and quality of monitoring varies widely from one clinic to the next.
How Effective It Actually Is
Ketamine is not a cure for depression, and not everyone responds. But for people who do respond, the speed and magnitude of relief can be dramatic. Clinical trial data shows that higher doses of racemic ketamine produce a moderate-to-large effect on depression scores compared to placebo, with effects that remain significant even after treatment ends. Lower doses still work but produce smaller effects.
Importantly, dropout rates in clinical trials were similar between ketamine and placebo groups, meaning people generally tolerated the treatment well enough to complete their courses. This matters because a drug that works but makes people feel terrible enough to quit isn’t practically useful. Ketamine’s side effects are mostly acute and time-limited, which helps with adherence.
The critical caveat is that ketamine’s antidepressant effects fade. A single infusion may relieve symptoms for days to a couple of weeks. Sustained benefit requires repeated dosing, which brings the long-term safety questions about bladder health, cognitive effects, and addiction potential into sharper focus. For many patients, ketamine serves best as a bridge: providing rapid relief while longer-acting treatments have time to take effect.